Exelixis | EXEL - Interest Income


Exelixis reported $14.21M in Interest Income for its fiscal quarter ending in June of 2026.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.06M 277K Mar/2026
Agios Pharmaceuticals USD 10.8M 1.62M Mar/2026
AstraZeneca USD 80M 7M Jun/2026
Bayer EUR 169M 39M Dec/2025
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Cytokinetics USD 11.02M 448K Mar/2026
Eisai JPY 3.11B 783M Mar/2024
Eli Lilly USD 65M 25M Sep/2025
Exelixis USD 14.21M 1.92M Jun/2026
Genmab DKK 14M 11M Mar/2026
Glaxosmithkline GBP 22M 4M Mar/2026
Incyte USD 38.12M 4.43M Jun/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
MacroGenics USD 1.55M 26K Mar/2026
Merck USD 35M 34M Mar/2026
Moderna USD 72M 2M Mar/2026
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD -0.04 115M Jun/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Sanofi EUR 60M 54M Mar/2026
Takeda JPY 24.61B 213.76B Jun/2026
Ultragenyx Pharmaceutical USD 6M 512K Mar/2026
Xencor USD 5.46M 741K Mar/2026